Philadelphia-based CARISMA Therapeutics Inc. secured $47 million in a Series B financing round that will be used to advance the development of the company’s novel chimeric antigen receptor macrophages (CAR-M) immunotherapies.
CARISMA Therapeutics Raises $47 Million to Advance CAR-M Program Into the Clinic
